Surmodics, Inc. (NASDAQ:SRDX) is expected to report fourth quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.08 per share.
Looking ahead, the full year income are expected at $ 0.22 per share on the revenues of $ 93.07 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 87.00 million ~ $ 91.00 million, where as bottomline are predicted in a range of $ -0.44 ~ $ -0.14 per share
Click Here For More Historical Outlooks Of Surmodics, Inc.
Previous Quarter Performance
Surmodics, Inc. unwinded income for the third quarter of $ 0.21 per share, from the revenue of $ 26.88 million. Wall street analysts are predicting, SRDX to report 3Q20 income of $ 0.19 per share from revenue of $ 23.75 million. The bottom line results beat street analysts by $ 0.02 or 10.53 percent, at the same time, top line results outshined analysts by $ 3.13 million or 13.18 percent.
Stock Performance
Shares of Surmodics, Inc. traded up $ 0.43 or 1.17 percent on Tuesday, reaching $ 37.23 with volume of 72.90 thousand shares. Surmodics, Inc. has traded high as $ 37.84 and has cracked $ 35.74 on the downward trend
According to the previous trading day, closing price of $ 37.23, representing a 66.82 % increase from the 52 week low of $ 22.06 and a 24.9 % decrease over the 52 week high of $ 49.00.
The company has a market capital of $ 508.20 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Surmodics, Inc. will be hosting a conference call at 5:00 PM eastern time on 4th November 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.surmodics.com
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
